Paraprotein-related renal disease and amyloid
暂无分享,去创建一个
[1] M. Dimopoulos,et al. Treatment of light chain (AL) amyloidosis with the combination of bortezomib and dexamethasone , 2007, Haematologica.
[2] M. Skinner,et al. XIth International Symposium on Amyloidosis , 2007 .
[3] Neil D Evans,et al. Efficient removal of immunoglobulin free light chains by hemodialysis for multiple myeloma: in vitro and in vivo studies. , 2006, Journal of the American Society of Nephrology : JASN.
[4] A. Dispenzieri,et al. Monoclonal gammopathy of undetermined significance, Waldenström macroglobulinemia, AL amyloidosis, and related plasma cell disorders: diagnosis and treatment. , 2006, Mayo Clinic proceedings.
[5] M. Haubitz,et al. Myeloma--new approaches to combined nephrological-haematological management. , 2006, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[6] Amit X Garg,et al. Plasma Exchange When Myeloma Presents as Acute Renal Failure , 2005, Annals of Internal Medicine.
[7] A. Dispenzieri,et al. Amyloidosis: diagnosis and management. , 2005, Clinical lymphoma & myeloma.
[8] F. Locatelli,et al. Light chain deposition disease with renal involvement: clinical characteristics and prognostic factors. , 2003, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[9] M. Pepys,et al. Outcome in systemic AL amyloidosis in relation to changes in concentration of circulating free immunoglobulin light chains following chemotherapy , 2003, British journal of haematology.
[10] V. D’Agati,et al. Fibrillary and immunotactoid glomerulonephritis: Distinct entities with different clinical and pathologic features. , 2003, Kidney international.
[11] J. Goujon,et al. Fibrillary glomerulonephritis and immunotactoid (microtubular) glomerulopathy are associated with distinct immunologic features. , 2002, Kidney international.
[12] L. Knudsen,et al. Renal failure in multiple myeloma: reversibility and impact on the prognosis , 2000, European journal of haematology.
[13] S. Jagannath,et al. CRITERIA FOR EVALUATING DISEASE RESPONSE AND PROGRESSION IN PATIENTS WITH MULTIPLE MYELOMA TREATED BY HIGH‐DOSE THERAPY AND HAEMOPOIETIC STEM CELL TRANSPLANTATION , 1998, British journal of haematology.
[14] C. Winearls,et al. Acute myeloma kidney. , 1995, Kidney international.
[15] A. Solomon,et al. Nephrotoxic potential of Bence Jones proteins. , 1991, The New England journal of medicine.